Verve Therapeutics shares dropped more than 30% early Tuesday after the company paused enrollment in a trial of its gene-editing treatment for heart disease.
Source link
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback
![im-706788.jpeg](https://manualproofer.com/wp-content/uploads/2024/04/im-706788-1068x712.jpeg)